Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 69

1.

Rate of serious infections in spondyloarthropathy patients treated with anti-tumour necrosis factor drugs: a survey from the Italian registry GISEA.

Atzeni F, Sarzi-Puttini P, Sebastiani M, Panetta V, Salaffi F, Iannone F, Carletto A, Foti R, Gremese E, Govoni M, Marchesoni A, Favalli E, Gorla R, Ramonda R, Ferraccioli G, Lapadula G; GISEA group.

Clin Exp Rheumatol. 2019 Feb 11. [Epub ahead of print]

PMID:
30767865
2.
3.

Cardiovascular disease in patients with rheumatoid arthritis: impact of classic and disease-specific risk factors.

Cavalli G, Favalli EG.

Ann Transl Med. 2018 Nov;6(Suppl 1):S82. doi: 10.21037/atm.2018.10.72. No abstract available.

4.

Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection.

Biggioggero M, Crotti C, Becciolini A, Favalli EG.

Drug Des Devel Ther. 2018 Dec 19;13:57-70. doi: 10.2147/DDDT.S150580. eCollection 2019. Review.

5.

The Management of Acute Anterior Uveitis Complicating Spondyloarthritis: Present and Future.

Biggioggero M, Crotti C, Becciolini A, Miserocchi E, Favalli EG.

Biomed Res Int. 2018 Oct 14;2018:9460187. doi: 10.1155/2018/9460187. eCollection 2018. Review.

6.

The profiling of axial spondyloarthritis patient candidate to a biologic therapy: Consensus from a Delphi-panel of Italian experts.

Favalli EG, Becciolini A, Caporali R, Todoerti M, Iannone F, Dinoia L, Sebastiani M, Spinella A, Gremese E, Cianci F, Atzeni F, Bandinelli F, Ferraccioli G, Lapadula G; GISEA Study Group.

Autoimmun Rev. 2018 Dec;17(12):1251-1258. doi: 10.1016/j.autrev.2018.07.002. Epub 2018 Oct 16. Review.

PMID:
30339886
7.

Switch or swap strategy in rheumatoid arthritis patients failing TNF inhibitors? Results of a modified Italian Expert Consensus.

Todoerti M, Favalli EG, Iannone F, Olivieri I, Benucci M, Cauli A, Mathieu A, Santo L, Minisola G, Lapadula G, Bucci R, Gremese E, Caporali R.

Rheumatology (Oxford). 2018 Oct 1;57(57 Suppl 7):vii42-vii53. doi: 10.1093/rheumatology/key195. Review.

PMID:
30289539
8.

Sarilumab: patient-reported outcomes in rheumatoid arthritis.

Crotti C, Biggioggero M, Becciolini A, Favalli EG.

Patient Relat Outcome Meas. 2018 Aug 20;9:275-284. doi: 10.2147/PROM.S147286. eCollection 2018. Review.

9.

The Expanded Risk Score in Rheumatoid Arthritis (ERS-RA): performance of a disease-specific calculator in comparison with the traditional prediction scores in the assessment of the 10-year risk of cardiovascular disease in patients with rheumatoid arthrit.

Salaffi F, Carotti M, Di Carlo M, Tardella M, Lato V, Becciolini A, Favalli EG, Giovagnoni A.

Swiss Med Wkly. 2018 Aug 22;148:w14656. doi: smw.2018.14656. eCollection 2018 Aug 13.

10.

Comments on "Short-term reasons for withdrawal and adverse events associated with apremilast therapy for psoriasis in real-world practice compared with in clinical trials: A multicenter retrospective study".

Favalli EG, Conti F, Atzeni F, Selmi C, D'Angelo S, Caporali R, Iannone F.

J Am Acad Dermatol. 2018 Dec;79(6):e119-e120. doi: 10.1016/j.jaad.2018.07.052. Epub 2018 Aug 7. No abstract available.

PMID:
30096421
11.

The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry.

Favalli EG, Becciolini A, Biggioggero M, Bertoldi I, Crotti C, Raimondo MG, Marchesoni A.

Drug Des Devel Ther. 2018 May 24;12:1421-1429. doi: 10.2147/DDDT.S162286. eCollection 2018.

12.

How advances in personalized medicine will change rheumatology.

Selmi C, Kon E, De Santis M, Favalli EG, Cimaz R, Generali E, Sinigaglia L.

Per Med. 2018 Mar;15(2):75-78. doi: 10.2217/pme-2017-0079. Epub 2018 Feb 2. No abstract available.

PMID:
29714121
13.

Challenges and Advances in Targeting Remission in Axial Spondyloarthritis.

Baraliakos X, Berenbaum F, Favalli EG, Olivieri I, Ostendorf B, Poddubnyy D, DE Vlam K.

J Rheumatol. 2018 Feb;45(2):153-157. doi: 10.3899/jrheum.170222. No abstract available.

14.

Sex and Management of Rheumatoid Arthritis.

Favalli EG, Biggioggero M, Crotti C, Becciolini A, Raimondo MG, Meroni PL.

Clin Rev Allergy Immunol. 2018 Jan 26. doi: 10.1007/s12016-018-8672-5. [Epub ahead of print] Review.

PMID:
29372537
15.

Tocilizumab after a first-line with anti-TNF in rheumatoid arthritis: a cost-consequence analysis in the Italian setting.

Iannazzo S, Benucci M, Favalli EG.

Clin Exp Rheumatol. 2018 May-Jun;36(3):479-485. Epub 2018 Jan 15.

PMID:
29352843
16.

Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis.

Galli M, Antinori S, Atzeni F, Meroni L, Riva A, Scirè C, Adorni F, Quartuccio L, Sebastiani M, AirĂ² P, Bazzichi L, Cristini F, Del Bono V, Manfredi A, Viapiana O, De Rosa F, Favalli E, Petrelli E, Salvarani C, Govoni M, Corcione S, Scrivo R, Sarmati L, Lazzarin A, Grassi W, Mastroianni C, Gaeta GB, Ferraccioli G, Cutolo M, De Vita S, Lapadula G, Matucci-Cerinic M, Armignacco O, Sarzi-Puttini P.

Clin Exp Rheumatol. 2017 Nov-Dec;35(6):1018-1028. Epub 2017 Nov 28. Review.

PMID:
29185961
17.

Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.

Favalli EG, Sinigaglia L, Becciolini A, Grosso V, Gorla R, Bazzani C, Atzeni F, Sarzi Puttini PC, Fusaro E, Pellerito R, Caporali R.

Int J Rheum Dis. 2018 Feb;21(2):422-430. doi: 10.1111/1756-185X.13199. Epub 2017 Oct 30.

PMID:
29082659
18.

The management of first-line biologic therapy failures in rheumatoid arthritis: Current practice and future perspectives.

Favalli EG, Raimondo MG, Becciolini A, Crotti C, Biggioggero M, Caporali R.

Autoimmun Rev. 2017 Dec;16(12):1185-1195. doi: 10.1016/j.autrev.2017.10.002. Epub 2017 Oct 14. Review.

PMID:
29037899
19.

Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugs.

Atzeni F, Carletto A, Foti R, Sebastiani M, Panetta V, Salaffi F, Bonitta G, Iannone F, Gremese E, Govoni M, Marchesoni A, Favalli EG, Gorla R, Ramonda R, Sarzi-Puttini P, Ferraccioli G, Lapadula G; GISEA group.

Joint Bone Spine. 2018 Jul;85(4):455-459. doi: 10.1016/j.jbspin.2017.08.003. Epub 2017 Sep 8.

PMID:
28893679
20.

Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors.

Monti S, Todoerti M, Codullo V, Favalli EG, Biggioggero M, Becciolini A, Montecucco C, Caporali R.

Mod Rheumatol. 2018 May;28(3):542-549. doi: 10.1080/14397595.2017.1367076. Epub 2017 Sep 7.

PMID:
28880727

Supplemental Content

Loading ...
Support Center